This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pujol, J.-L. Articles by Michel, F.-B. Search for Related Content PubMed PubMed Citation Articles by Pujol, J.-L. Articles by Michel, F.-B.

Serum Fragment of Cytokeratin Subunit 19 Measured by CYFRA 21-1 Immunoradiometric Assay as a Marker of Lung Cancer

Clinique des Maladies Respiratoires, Université de Montpellier, Hôpital Aiguelongue, 34059 Montpellier Cedex [J-L. P., F-B. M.]; Centre Régional de Lutte contre le Cancer, Laboratoire de Radio-Analyses, 34094 Montpellier Cedex [J. G., H. P.]; Département de l'Information Médicale, Hôpital Gaston Doumergue, 30000 Nimes [J-P. D.]; and Centre Paul Papin, 2, Rue Moll, 49036 Angers [A. D.], France

Cytokeratin 19 is a subunit of cytokeratin intermediate filament expressed in simple epithelia and their malignant counterparts. Therefore, it is expressed by respiratory epithelium cells and has been detected in lung cancer specimens. An immunoradiometric assay was used to detect a fragment of the cytokeratin 19, referred to as CYFRA 21-1, in the serum of 165 patients with histologically proved lung cancer (128 non-small cell and 37 small cell lung cancers). This prospective study was conducted to evaluate the reliability of this immunoradiometric assay and to identify the relationship between serum CYFRA 21-1 and different features of lung cancer including prognosis. The minimal detectable concentration detected by this assay was 0.06 ng/ml. The reliability of the immunoradiometric assay was demonstrated by the linear relationship between CYFRA 21-1 measurement and dilution of the serum, the reproducibility of the dosage in intraassay and interassay, and the high sensitivity of the method in discriminating low CYFRA 21-1 concentrations. Using a threshold of 3.6 ng/ml, sensitivity and specificity were 0.52 and 0.87, respectively. The sensitivity of the marker was highest in squamous cell carcinoma and lowest in small cell carcinoma. In non-small cell lung cancer patients, the marker varied significantly according to both stage of the disease (Kruskal-Wallis, 13.7; P < 0.005) and performance status (Kruskal-Wallis, 9.16; P < 0.05) inasmuch as a high serum CYFRA 21-1 level was associated with advanced stages, mediastinal lymph nodes, and poor performance status. Consequently, the marker was significantly lower in patients who were operated upon when compared with unresectable ones. Lung cancer patients with serum CYFRA 21-1 over 3.6 ng/ml proved to have a significantly shorter overall survival than those with a normal serum level (log rank, P = 0.007; Wilcoxon, P = 0.001). The negative prognostic effect of CYFRA 21-1 was highly significant in squamous cell carcinomas whereas it was nonsignificant for the other histologies. In Cox's model analysis, performance status, stage grouping, and CYFRA 21-1 were the only significant determinants of survival. This study supports the use of the serum fragment of cytokeratin subunit 19 CYFRA 21-1 as an independent prognostic marker of squamous cell carcinoma of the lung.

¹ To whom requests for reprints should be addressed.

Received 7/ 2/92. Accepted 10/20/92.

This article has been cited by other articles:

				S. L. Sheng, G. Huang, B. Yu, and W. X. Qin Clinical Significance and Prognostic Value of Serum Dickkopf-1 Concentrations in Patients with Lung Cancer Clin. Chem., September 1, 2009; 55(9): 1656 - 1664. [Abstract] [Full Text] [PDF]

				H. Suzuki, S. Ishikawa, H. Satoh, H. Ishikawa, M. Sakai, T. Yamamoto, M. Onizuka, and Y. Sakakibara Preoperative CYFRA 21-1 levels as a prognostic factor in c-stage I non-small cell lung cancer Eur. J. Cardiothorac. Surg., October 1, 2007; 32(4): 648 - 652. [Abstract] [Full Text] [PDF]

				G. Paone, E. Nicastri, G. Lucantoni, R. Dello Iacono, P. Battistoni, A. L. D'Angeli, and G. Galluccio Endobronchial Ultrasound-Driven Biopsy in the Diagnosis of Peripheral Lung Lesions Chest, November 1, 2005; 128(5): 3551 - 3557. [Abstract] [Full Text] [PDF]

				N. Ishikawa, Y. Daigo, W. Yasui, K. Inai, H. Nishimura, E. Tsuchiya, N. Kohno, and Y. Nakamura ADAM8 as a Novel Serological and Histochemical Marker for Lung Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8363 - 8370. [Abstract] [Full Text] [PDF]

				G. Kramer, H. Erdal, H. J. M. M. Mertens, M. Nap, J. Mauermann, G. Steiner, M. Marberger, K. Biven, M. C. Shoshan, and S. Linder Differentiation between Cell Death Modes Using Measurements of Different Soluble Forms of Extracellular Cytokeratin 18 Cancer Res., March 1, 2004; 64(5): 1751 - 1756. [Abstract] [Full Text] [PDF]

				S.-J. Ding, Y. Li, Y.-X. Tan, M.-R. Jiang, B. Tian, Y.-K. Liu, X.-X. Shao, S.-L. Ye, J.-R. Wu, R. Zeng, et al. From Proteomic Analysis to Clinical Significance: Overexpression of Cytokeratin 19 Correlates with Hepatocellular Carcinoma Metastasis Mol. Cell. Proteomics, January 1, 2004; 3(1): 73 - 81. [Abstract] [Full Text] [PDF]

				S K Mohanty and P Dey Serous effusions: diagnosis of malignancy beyond cytomorphology. An analytic review Postgrad. Med. J., October 1, 2003; 79(936): 569 - 574. [Abstract] [Full Text] [PDF]

				M. Nakayama, H. Satoh, H. Ishikawa, M. Fujiwara, H. Kamma, M. Ohtsuka, and K. Sekizawa Cytokeratin 19 Fragment in Patients With Nonmalignant Respiratory Diseases Chest, June 1, 2003; 123(6): 2001 - 2006. [Abstract] [Full Text] [PDF]

				R. T. Vollmer, R. Govindan, S. L. Graziano, G. Gamble, J. Garst, M. J. Kelley, and R. H. Christenson Serum CYFRA 21-1 in Advanced Stage Non-Small Cell Lung Cancer: An Early Measure of Response Clin. Cancer Res., May 1, 2003; 9(5): 1728 - 1733. [Abstract] [Full Text] [PDF]

				J. Kulpa, E. Wojcik, M. Reinfuss, and L. Kolodziejski Carcinoembryonic Antigen, Squamous Cell Carcinoma Antigen, CYFRA 21-1, and Neuron-specific Enolase in Squamous Cell Lung Cancer Patients Clin. Chem., November 1, 2002; 48(11): 1931 - 1937. [Abstract] [Full Text] [PDF]

				M. Sugita, M. Geraci, B. Gao, R. L. Powell, F. R. Hirsch, G. Johnson, R. Lapadat, E. Gabrielson, R. Bremnes, P. A. Bunn, et al. Combined Use of Oligonucleotide and Tissue Microarrays Identifies Cancer/Testis Antigens as Biomarkers in Lung Carcinoma Cancer Res., July 15, 2002; 62(14): 3971 - 3979. [Abstract] [Full Text] [PDF]

				J. G. Brockmann, H. St. Nottberg, B. Glodny, A. Heinecke, and N. J. Senninger CYFRA 21-1 Serum Analysis in Patients with Esophageal Cancer Clin. Cancer Res., November 1, 2000; 6(11): 4249 - 4252. [Abstract] [Full Text] [PDF]

				Y. Tamai, T.-o Ishikawa, M. R. Bosl, M. Mori, M. Nozaki, H. Baribault, R. G. Oshima, and M. M. Taketo Cytokeratins 8 and 19 in the Mouse Placental Development J. Cell Biol., October 30, 2000; 151(3): 563 - 572. [Abstract] [Full Text] [PDF]

				M. Morifuji, S.’i. Taniguchi, H. Sakai, Y. Nakabeppu, and M. Ohishi Differential Expression of Cytokeratin after Orthotopic Implantation of Newly Established Human Tongue Cancer Cell Lines of Defined Metastatic Ability Am. J. Pathol., April 1, 2000; 156(4): 1317 - 1326. [Abstract] [Full Text] [PDF]

				I. Doweck, M. Barak, E. Greenberg, N. Uri, J. Kellner, M. Lurie, and N. Gruener Cyfra 21-1: A New Potential Tumor Marker for Squamous Cell Carcinoma of Head and Neck Arch Otolaryngol Head Neck Surg, February 1, 1995; 121(2): 177 - 181. [Abstract] [PDF]